Cited by 103

The High Mobility Group A1 Gene: Transforming Inflammatory Signals into Cancer?

Resar, Linda M.S.·2010·Cancer Research

Abstract

High mobility group A1 (HMGA1) is highly expressed during embryogenesis and in poorly differentiated cancers, and high levels portend a poor prognosis in some tumors. HMGA1 induces oncogenic transformation in cultured cells and causes aggressive cancers in transgenic mice, whereas blocking it interferes with transformation in experimental models. These findings suggest a pivotal role for HMGA1 in cancer. This review focuses on two recently described HMGA1 transcriptional targets that mediate inflammatory signals and drive malignant transformation because they could serve as biomarkers or therapeutic targets. Further elucidation of HMGA1 function in transformation promises to have a major impact on our war on cancer. Cancer Res; 70(2); 436–9

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-1212

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HMGA1 promotes an inflammatory transcriptional profile, at least in part by increasing Cox-2 and STAT-3 levels.

    “Particularly relevant to the role of miR-181 repression of HMGA1 in the inflammatory response, HMGA1 has been shown to promote an inflammatory transcriptional profile, at least in part by increasing Cox-2 and STAT-3 levels (Resar, 2010 for a review; Schuldenfrei et al., 2011).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 21

  1. [1]Lund T Holtman J Frederiksen M Laland SG On the presence of two new high mobility group-like proteins in HeLa S3 cells FEBS Lett 1983 152 163 7 6297996
  2. [2]Bustin M Regulation of DNA-dependent activities by the functional motifs of the high-obility-group chromosomal proteins Mol Cell Biol 1999 19 5237 46 10409715 PMC84367
  3. [3]Du W Thanos D Maniatis T Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements Cell 1993 74 887 98 8374955
  4. [4]Johnson KR Lehn DA Elton TS Barr PJ Reeves R The chromosomal high mobility group protein HMG-I(Y): Complete murine cDNA sequence, genomic structure, and tissue expression J Biol Chem 1998 18 18338 42 3192537
  5. [5]Zhou K Kas E Gonzalez E Laemmli UK SAR-dependent mobilization of histone H1 by HMG-I/Y in vivo:HMG-I/Y is enriched in H1-depleted chromatin EMBO J 1993 12 3237 47 8344261 PMC413591
  6. [6]Chiappetta G Avantaggiato V Visconti R High level expression of the HMGI(Y) gene during embryonic development Oncogene 1996 13 2439 46 8957086
  7. [7]Lanahan A Williams JB Sanders LK Nathans D Growth-factor induced delayed early response genes Mol Cell Biol 1992 12 3919 29 1508193 PMC360271
  8. [8]Pomeroy SL Tamayo P Gaasenbeek M Prediction of central nervous system embryonal tumour outcome based on gene expression Nature 2002 415 436 42 11807556
  9. [9]Wood LJ Mukherjee M Dolde CE HMG-I/Y: A new c-Myc target gene and potential oncogene Mol Cell Biol 2000 20 5490 2 10891489 PMC86000
  10. [10]Wood LJ Maher JF Bunton TE Resar LMS The oncogenic properties of the HMG-I gene family Cancer Res 2000 60 4256 61 10945639
  11. [11]Xu Y Felder TS Bhattacharya R The HMG-I oncogene causes highly penetrant, metastatic lymphoid malignancy in transgenic mice and is overexpressed in human lymphoid malignancy Cancer Res 2004 64 3371 5 15150086
  12. [12]Scala S Portella G Fedele M Chiapetta G Fusco A Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias Proc Natl Acad, Sci USA 2000 97 4256 61 10759549 PMC18219
  13. [13]Reeves R Ederg DD Li Y Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells Mol Cell Biol 2001 21 575 94 11134344 PMC86623
  14. [14]Fedele M Pentimalli F Baldassarre G Transgenic mice overexpressing the wild-type form of the HMGA1 gene develp mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas Cancer Res 2005 24 3427 35 15735694
  15. [15]Tesfaye A Di Cello F Hillion J HMGA1a Up-regulates Cox-2 in uterine tumorigenesis Cancer Res 2007 67 3998 4004 17483309
  16. [16]Di Cello F Hillion J Aderinto A COX-2 inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human uterine cancer xenografts Mol Cancer Ther 2008 7 2090 95 18645019 PMC2593419
  17. [17]Hillion J Dhara S Sumter TF The HMGA1a-STAT3 axis: an “Achilles heel” for acute leukemia? Cancer Res 2008 68 10121 7 19074878 PMC2913892
  18. [18]Ben-Porath I Thomson MW Carey VJ Ge R Bell GW Regev A Weinberg RA 2008 An embryonic stem cell-like signature in poorly differentiated aggressive tumors Nat Genetics 40 499 507 18443585 PMC2912221
  19. [19]Fedele M Fidanza V Battista S Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice Cancer Res 2006 66 2536 43 16510570
  20. [20]Ji YS Xu Q Schmedtje JF Hypoxia induces high mobility-group protein I(Y) and transcription of cycooxygenase vascular endothelium Circ Res 1998 83 295 304 9710122
  21. [22]Adair JE Maloney SC Dement GA Wertzler KJ Smerdon MJ Reeves R High- mobility group A1 proteins inhibit expression of nucleotide excision repair factor xeroderma pigmentosum group A Cancer Res 2007 67 6044 52 17616660

Cited by

Sorted by citations

Authors
Resar, L. M. S.
Affiliations
Author's Affiliation: The Johns Hopkins University School of Medicine, Baltimore, Maryland
Venue
Cancer Research
Published
2010-01-13
Volume
70
Issue
2
Pages
436-439
ISSN
  • 0008-5472
  • 1538-7445
Cited by
103
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review